STOCK TITAN

AbbVie (ABBV) director Rapp receives 1,118 restricted stock units and now holds 45,964 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

AbbVie Inc. director Edward J. Rapp received an award of 1,118 restricted stock units under the AbbVie Amended and Restated 2013 Incentive Stock Program. Each unit will convert into one share of AbbVie common stock on the earlier of his separation from service, death, or a change in control as defined in the program. Following this grant, Rapp holds 45,964 AbbVie shares directly, including 10,388 shares previously held indirectly through a spouse’s trust that are now held directly.

Positive

  • None.

Negative

  • None.
Insider RAPP EDWARD J
Role null
Type Security Shares Price Value
Grant/Award Common Stock, $0.01 par value 1,118 $0.00 --
Holdings After Transaction: Common Stock, $0.01 par value — 45,964 shares (Direct, null)
Footnotes (1)
  1. These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Total holdings include 10,388 shares in trust previously held indirectly by spouse, now held directly.
RSU grant 1,118 units Restricted stock units awarded on 2026-05-08
Shares after transaction 45,964 shares Total AbbVie shares held directly after grant
Trust shares now direct 10,388 shares Previously held indirectly by spouse, now direct
Grant price $0.00 per share Stated price for awarded restricted stock units
restricted stock units financial
"These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
AbbVie Amended and Restated 2013 Incentive Stock Program financial
"awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program"
change in control financial
"on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
RAPP EDWARD J

(Last)(First)(Middle)
1 N. WAUKEGAN ROAD

(Street)
NORTH CHICAGO ILLINOIS 60064

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, $0.01 par value05/08/2026A1,118(1)A$045,964(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
2. Total holdings include 10,388 shares in trust previously held indirectly by spouse, now held directly.
/s/ T.O. Odutayo, attorney-in-fact for Edward J. Rapp05/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did AbbVie (ABBV) director Edward J. Rapp report in this Form 4?

Edward J. Rapp reported receiving 1,118 restricted stock units of AbbVie common stock. These units were granted as equity compensation and increase his direct holdings to 45,964 shares, reflecting routine director compensation rather than an open-market stock purchase or sale.

How many AbbVie (ABBV) shares does Edward J. Rapp hold after this transaction?

After the reported award, Edward J. Rapp holds 45,964 AbbVie shares directly. This total includes 10,388 shares previously held indirectly in a spouse’s trust, which are now reported as direct holdings, providing a clearer view of his beneficial ownership position.

What kind of equity did Edward J. Rapp receive from AbbVie (ABBV)?

He received 1,118 restricted stock units under AbbVie’s Amended and Restated 2013 Incentive Stock Program. Each unit represents a right to receive one share of common stock, payable in shares at specific triggering events instead of being an immediate cash or stock payment.

When will Edward J. Rapp’s AbbVie (ABBV) restricted stock units be paid out?

The restricted stock units will be paid in AbbVie common shares on a one-to-one basis. Payment occurs on the earlier of his separation from service, his death, or a change in control of AbbVie, as defined in the company’s incentive stock program.

Was there any cash paid for the AbbVie (ABBV) shares reported in this Form 4?

No cash purchase is indicated; the 1,118 units were granted at a stated price of $0.00 per share. This reflects a compensation award of restricted stock units rather than an open-market transaction, consistent with typical director equity compensation practices.

How did the AbbVie (ABBV) filing describe shares previously held by Edward J. Rapp’s spouse?

The filing notes total holdings include 10,388 AbbVie shares in a trust that were previously held indirectly by his spouse. These shares are now reported as held directly, consolidating Rapp’s beneficial holdings under his direct ownership in the disclosure.